12.15
Katherine Unger Baillie
Science News Officer
kbaillie@upenn.edu
Cancer Research
CAR T cell therapy leads to lasting remissions
In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor CAR T cell therapy Kymriah® led to long-lasting remissions in patients with non-Hodgkins lymphoma.
FDA approves new targeted drug for leukemia
The drug is the first to target common mutations associated with relapse and short survival in acute myeloid leukemia.
A link between anti-malaria drugs and cancer treatments, explained
The Abramson Cancer Center study is the first to identify what drugs known as chloroquines are targeting when used for cancer treatment.
The ‘immunorevolution’ has begun
Penn Medicine experts gathered for a panel discussion about their innovative new approach to harness the body’s own immune system to fight cancer.
Future fertility: Giving hope to men who received childhood cancer treatment
Researchers have discovered a way to grow human stem cells destined to become mature sperm in an effort to provide fertility options later in life to males who are diagnosed with cancer and undergo chemotherapy and radiation as children.
Abramson Cancer Center receives $10.7 million to study CAR T cells in solid tumors
A new program project grant from the National Cancer Institute (NCI) will fund research by the Translational Center of Excellence for Lung Cancer Immunology for experimental approaches in lung cancer and mesothelioma.
Skin cream use OK’d during radiation therapy
A new study challenges common advice given to patients about whether topical creams increase radiation dose during cancer treatment.
Blood test identifies more treatable cancer mutations than biopsies alone
A new study shows patients with treatable mutations identified by liquid biopsies rather than tissue biopsies also largely respond to therapy.
‘Cancer in all forms is our enemy’
Robert H. Vonderheide, the Abramson Cancer Center director, talks innovation, discoveries, FDA approvals, and how to deliver top-of-the-line cancer care.
Immune cells involved in triple-negative breast cancer could offer future therapeutic target
New research led by Rumela Chakrabarti reveals how immune cells called myeloid-derived immunosuppressor cells contribute to the progression of triple-negative breast cancer, a particularly aggressive cancer. Pairing chemotherapy with a drug that blocks these cells may one day help stem its growth.
Media Contact
Experts
In the News
HealthDay News
For Breast Cancer Patients, Less Time on Hormonal Meds?
Susan Domchek of the Perelman School of Medicine and the Abramson Cancer Center comments on hormonal therapy.
FULL STORY →
Nature
Acupuncture in Cancer Study Reignites Debate About Controversial Technique
Rollin Gallagher of the Perelman School of Medicine comments on a clinical trial that focused on whether acupuncture can relieve pain in cancer patients.
FULL STORY →